| Approximately 30% of people with Alzheimer’s disease experience psychosis—hallucinations and delusions—with no approved treatment. That gap is driving a new wave of innovation across the industry, including at biotechs like Acadia that are powered by precision medicine, data innovation, globalization, and patient empowerment. The goal is clear: finally deliver a treatment option that addresses an unmet need for one of Alzheimer’s disease’s most devastating challenges. |
